OCUL Ocular Therapeutix, Inc.
$6.72▲ +3.86%
Healthcare
Other
After hours
$6.88▲ +2.38%
Oct 27, 4:30 PM ET
Volume 2.22M
Avg Volume (10D) 3.06M
Key Metrics & Fundamentals
Market Cap
$1.48B
P/E Ratio
–
Div Yield
0.00%
52W Range
6.00 - 16.44
% vs 50 MA
-25.81%
% vs 200 MA
-26.72%
RSI-14
37.1
MACD Histogram
+0.0500
Beta (1Y vs SPY)
1.16
Free Cash Flow
-$70.64M
Gross Rev
$13.48M
Gross Profit
$11.46M
EBITDA
-$74.81M
COGS
$2.01M
Operating Exp
$93.57M
Operating Income
-$82.11M
EBIT
-$82.11M
Pretax Income
-$78.76M
Net Income
-$78.76M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
MarketBeat · Oct 20, 2026 12:04 PM ET
Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says
MT Newswires · Oct 20, 2026 12:03 PM ET
Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know
StockStory · Oct 16, 2026 4:51 PM ET
1 Russell 2000 Stock with Solid Fundamentals and 2 We Avoid
StockStory · Oct 15, 2026 6:48 AM ET
3 Healthcare Stocks We Find Risky
StockStory · Oct 13, 2026 6:11 AM ET
3 Unprofitable Stocks Walking a Fine Line
StockStory · Oct 12, 2026 12:15 PM ET
UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target
MT Newswires · Oct 12, 2026 7:35 AM ET
1 Cash-Burning Stock for Long-Term Investors and 2 Facing Headwinds
StockStory · Oct 9, 2026 7:39 AM ET
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 9, 2026 7:00 AM ET
Top 4 Healthcare Stocks Backed by Raymond James Analysts
Investing.com · Oct 8, 2026 10:09 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OCUL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.